| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.9 |